慢性淋巴细胞白血病
医学
氟达拉滨
白血病
中性粒细胞减少症
嘌呤类似物
内科学
克拉屈滨
淋巴瘤
胃肠病学
抗代谢物
核苷类似物
化疗
免疫学
核苷
嘌呤
环磷酰胺
化学
生物化学
酶
立体化学
作者
Naosuke Arima,H Mizoguchi,S Shirakawa,Masao Tomonaga,Kiyoshi Takatsuki,R Ohno
出处
期刊:PubMed
日期:1999-04-01
卷期号:26 (5): 619-29
被引量:7
摘要
We have conducted a phase I clinical study of fludarabine phosphate, a new purine nucleoside derivative, in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma. The patients were given intravenous administration at a dose of 15 mg/m2/day followed by 20 mg/m2/day and 25 mg/m2/day, each dose given consecutively for 5 days. The dose limiting factors were thrombocytopenia and neutropenia. The thrombocyte count and neutrocyte count dropped to their lowest value in week 1 to 2 after administration, but the changes were reversible, and these counts recovered in most patients. The maximum tolerated dose of the study drug was 25 mg/m2/day, and it was decided to administer 20 mg/m2/day as the recommended dose for the subsequent phase II clinical study.
科研通智能强力驱动
Strongly Powered by AbleSci AI